1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Real-time Estimate Cboe BZX  -  09:53 2022-08-08 am EDT
201.14 USD   +3.43%
07:17aBEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
07:09aNomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
06:08aNomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: Beigene

06/22/2022 | 05:56pm EDT


© MT Newswires 2022
All news about BEIGENE, LTD.
07:17aBEIGENE, LTD. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
07:09aNomura Adjusts BeiGene's Price Target to $286.31 From $277.35, Maintains Buy Rating
MT
06:08aNomura Adjusts Beigene's Price Target to HK$172.89 From HK$167.48, Keeps at Buy
MT
08/05WALL STREET STOCK EXCHANGE : Another case of good news is bad news
MS
08/05ANALYST RECOMMENDATIONS : Eli Lilly, KLA, Kellogg, Epam Systems, BeiGene...
MS
08/05BeiGene Shares Gain After Doubling of Second-Quarter Revenue
DJ
08/04BeiGene Q2 Net Loss per ADS Widens as Revenue Rises; Shares Surge
MT
08/04BEIGENE : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/04Earnings Flash (BGNE) BEIGENE Posts Q2 Revenue $341.6M
MT
08/04BEIGENE, LTD. : Results of Operations and Financial Condition, Other Events, Financial Sta..
AQ
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 393 M - -
Net income 2022 -1 594 M - -
Net cash 2022 2 960 M - -
P/E ratio 2022 -14,6x
Yield 2022 -
Capitalization 20 122 M 20 122 M -
EV / Sales 2022 12,3x
EV / Sales 2023 8,79x
Nbr of Employees 8 500
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 194,47 $
Average target price 280,24 $
Spread / Average Target 44,1%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-28.22%20 122
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093